FVIII concentrate
PreclinicalSmall molecule
FVIII concentrate is one of 17 small molecule programs targeting Hemophilia. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Hemophilia
#DrugCompanyPhaseTrials
1Hemlibra
RocheApproved
Videx
Bristol-Myers SquibbApproved
Hivid
CConrado Roberto Hoffmann Filho
Approved
Zerit
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Cyklokapron
JJ Molner
Approved
Crixivan
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Qfitlia
GGenzyme, a Sanofi Company
Approved
Antithrombin Concentrate (ATIIIC)
SanofiPhase 3
Foscenvivint
KKiminori Kimura, MD
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FVIII concentrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details